Glanzmann thrombasthenia Medical Services in China

Glanzmann thrombasthenia (GT) is a rare, inherited autosomal recessive bleeding disorder characterized by defective platelet aggregation due to quantitative or qualitative deficiencies of the αIIbβ3 integrin glycoprotein complex—also known as the fibrinogen receptor—on the platelet surface. This glycoprotein is essential for platelet binding to fibrinogen, von Willebrand factor, and other adhesive ligands during hemostasis; its dysfunction results in severely impaired platelet plug formation despite normal platelet counts and morphology. Pathogenesis stems from biallelic loss-of-function mutations in either ITGA2B (encoding αIIb) or ITGB3 (encoding β3), leading to absent, reduced, or nonfunctional αIIbβ3 receptors. As a consequence, patients exhibit prolonged bleeding time, mucocutaneous bleeding (e.g., epistaxis, gingival bleeding, menorrhagia), easy bruising, and excessive bleeding after trauma or surgery—though spontaneous deep tissue or intracranial hemorrhage is uncommon. GT is pan-ethnic but shows higher prevalence in populations with increased consanguinity, such as Middle Eastern, Indian, and Romani communities. Epidemiologically, GT affects approximately 1 in 1,000,000 individuals worldwide, with no gender predilection. Risk factors include parental consanguinity and family history of unexplained bleeding diathesis; genetic counseling and prenatal testing are recommended for at-risk families. Quality of life is significantly impacted: chronic anemia from recurrent bleeding may cause fatigue and reduced exercise tolerance; adolescents and women face psychosocial challenges related to menorrhagia and fear of surgical procedures; children often experience school absences due to bleeding episodes or prophylactic interventions. While GT is lifelong and currently incurable, supportive management—including antifibrinolytics (e.g., tranexamic acid), platelet transfusions (for major bleeding or surgery), recombinant activated factor VIIa (rFVIIa), and emerging therapies like gene editing and lentiviral gene therapy in clinical trials—enables most patients to achieve near-normal functional status. However, alloimmunization against αIIbβ3 following repeated platelet transfusions remains a serious complication, limiting future transfusion efficacy and increasing perioperative risk. Comprehensive care requires multidisciplinary coordination among hematologists, gynecologists, dentists, surgeons, and psychologists within specialized coagulation centers.

Glanzmann thrombasthenia (GT) is a rare, autosomal recessive inherited bleeding disorder characterized by defective platelet aggregation due to quantitative or qualitative deficiencies of the αIIbβ3 integrin receptor (glycoprotein IIb/IIIa), essential for fibrinogen-mediated platelet cross-linking. Patients present with mucocutaneous bleeding—epistaxis, gingival hemorrhage, menorrhagia, easy bruising—and prolonged bleeding after trauma or surgery; however, platelet counts and morphology remain normal. Diagnosis relies on clinical history, prolonged bleeding time, absence of platelet aggregation in response to ADP, epinephrine, collagen, and ristocetin (with preserved ristocetin-induced platelet activation), and definitive confirmation via flow cytometry or genetic testing for biallelic pathogenic variants in ITGA2B or ITGB3 genes. Management is multidisciplinary, coordinated by hematology specialists, and tailored to bleeding severity, surgical needs, and reproductive planning.

Conservative treatment forms the cornerstone of long-term GT management and emphasizes prevention and non-pharmacologic interventions. Patients must avoid antiplatelet agents (e.g., aspirin, NSAIDs, clopidogrel) and anticoagulants unless absolutely indicated and carefully monitored. Dental care requires prophylactic measures: routine oral hygiene, fluoride application, and early referral to hematologists before any invasive dental procedure. Topical hemostatic agents—including tranexamic acid mouthwash (5% solution, rinsed 3–4 times daily for 5–7 days pre- and post-procedure), nasal packing with oxidized cellulose or fibrin sealant, and pressure dressings—are routinely employed for minor bleeding. Hormonal therapy (e.g., combined oral contraceptives or levonorgestrel-releasing intrauterine systems) is first-line for menorrhagia in women of childbearing age, reducing menstrual blood loss by up to 50–70%. Iron supplementation is initiated promptly in cases of iron-deficiency anemia secondary to chronic blood loss. Comprehensive patient education—including recognition of warning signs (e.g., prolonged oozing, hematuria, melena), emergency contact protocols, and use of medical alert identification—is integral to conservative care.

Pharmacotherapy remains supportive rather than curative. Antifibrinolytics—particularly tranexamic acid (10–25 mg/kg orally three to four times daily, adjusted for renal function)—are the most widely used and effective agents for mucosal bleeding prophylaxis and perioperative management. Aminocaproic acid serves as an alternative but is less potent and associated with higher rates of gastrointestinal intolerance. Recombinant activated factor VII (rFVIIa; NovoSeven®) is the primary hemostatic agent for major bleeding or surgical procedures when platelet transfusions are unavailable or contraindicated (e.g., due to alloimmunization). Dosing ranges from 60–90 µg/kg IV bolus, repeated every 2–3 hours for 2–3 doses, or continuous infusion at 1.5–2.5 µg/kg/min for 12–24 hours. While highly effective, rFVIIa carries thrombotic risk (especially in elderly or immobilized patients) and requires careful risk-benefit assessment. Platelet transfusions remain critical for life-threatening hemorrhage or high-risk surgeries but are limited by alloimmunization—up to 30–50% of chronically transfused GT patients develop HLA or HPA antibodies, rendering subsequent transfusions ineffective. Therefore, transfusion should be reserved for emergencies and administered only after HLA-matched or crossmatched platelets are secured. Desmopressin (DDAVP) has inconsistent efficacy in GT and is not recommended outside investigational settings.

Surgical treatment is not disease-modifying but addresses complications or enables definitive interventions. Splenectomy is generally avoided in GT, as it does not correct the intrinsic platelet defect and may increase thrombotic risk without improving hemostasis. Hematopoietic stem cell transplantation (HSCT) remains the only potentially curative option but is reserved for severe, refractory cases with life-threatening bleeding and a matched sibling donor due to significant morbidity (graft-versus-host disease, infection, transplant-related mortality ~15–25%). Gene therapy is under active investigation in preclinical and early-phase clinical trials but is not yet standard-of-care. Surgical procedures—including dental extractions, tonsillectomy, or gynecologic interventions—require meticulous preoperative planning: baseline platelet antibody screening, rFVIIa availability, and coordination with a specialized hemophilia/GT treatment center. Minimally invasive techniques and intraoperative hemostatic adjuncts (e.g., argon beam coagulation, topical thrombin, fibrin glue) are strongly preferred.

China offers distinct advantages in GT management, particularly through its nationally integrated Hemophilia Treatment Network (HTN), established under the National Health Commission. Over 120 designated HTN centers—including top-tier institutions such as Peking Union Medical College Hospital, Shanghai Ruijin Hospital, and West China Hospital—provide standardized, protocol-driven care aligned with WFH and ISTH guidelines. rFVIIa is approved and reimbursed under China’s National Reimbursement Drug List (NRDL) for GT since 2021, significantly improving access. Domestic biosimilar rFVIIa (e.g., SinoBiopharm’s SB-001) has reduced acquisition costs by ~40% compared to imported products. Furthermore, China’s centralized platelet donor registry and HLA-typing infrastructure facilitate rapid identification of compatible donors, mitigating alloimmunization risks. The Chinese Society of Hematology publishes biennial GT Clinical Practice Guidelines, incorporating real-world data from the China Hemophilia Registry, which now includes >1,800 GT patients—the largest national cohort globally. Telehematology platforms enable remote monitoring and urgent consultation across provinces, enhancing continuity of care in rural regions.

Recovery and long-term follow-up emphasize proactive, individualized strategies. Patients should undergo annual comprehensive assessments: CBC, ferritin, liver/kidney function, platelet antibody screening (if transfused), and psychosocial evaluation. Women require gynecologic surveillance every 6–12 months, including pelvic ultrasound and endometrial biopsy if abnormal uterine bleeding persists despite hormonal therapy. Vaccination against hepatitis A/B is mandatory prior to any transfusion exposure. Physical activity should be encouraged—swimming, walking, and cycling are low-risk—but contact sports (e.g., rugby, boxing) are contraindicated. Pregnancy necessitates preconception counseling, multidisciplinary care (hematologist, obstetrician, anesthesiologist), and delivery planning at a tertiary center with rFVIIa and HLA-matched platelets available; vaginal delivery is preferred over cesarean unless obstetric indications exist. Psychosocial support—including peer networks facilitated by the China Hemophilia Association and cognitive-behavioral therapy for anxiety related to bleeding episodes—is strongly recommended. With optimized care, life expectancy approaches normal, and quality of life markedly improves. Ongoing research into gene editing (e.g., CRISPR-Cas9 correction of ITGA2B in autologous CD34+ cells) and next-generation platelet mimetics promises transformative advances within the next decade.